INTRODUCTION
G protein-coupled receptors (GPCRs) comprise the largest family of cell surface receptors involved in signal transduction (Santos et al., 2017; Wacker et al., 2017) . In recent years, there has been a realization that a number of GPCRs may play important roles in cancer (Nieto Gutierrez and McDonald, 2018; De Francesco et al., 2017; Bar-Shavit et al., 2016; Liu et al., 2016; O'Hayre et al., 2013) . For example, b-adrenoceptors are intimately involved in the pathogenesis of infantile hemangioma (Leaute-Labreze et al., 2008; Stiles et al., 2012) and have been implicated in the progression of several malignant tumor types including angiosarcoma, breast cancer, and ovarian cancer (Rains et al., 2017; Watkins et al., 2015; Armaiz-Pena et al., 2013; Choy et al., 2016; Le et al., 2016; Sloan et al., 2010) . In particular, activation of b 2 -adrenoceptors by physiological stress can switch cancer cells to an invasive metastatic phenotype (Sloan et al., 2010; Chang et al., 2016; Creed et al., 2015) . The classical b-adrenoceptor antagonist, propranolol, has clinical efficacy for the treatment of infantile hemangiomas and angiosarcomas (Leaute-Labreze et al., 2008 Chow et al., 2015; Stiles et al., 2013) and prevents the progression of cancer in mouse models (Sloan et al., 2010) and in patients (Shaashua et al., 2017; De Giorgi et al., 2018) .
Most cells in the body are close to vasculature allowing easy access of drugs from circulation. However, in tumors, hypoxic regions and tortured non-functional vasculature (Folkman, 1971; Ferrara, 2001; Carmeliet and Jain, 2011; Wong et al., 2015) result in a population of cells that are distant from blood vessels (Carmeliet and Jain, 2011; Minchinton and Tannock, 2006) . This distance may hinder the extent to which drugs reach these cells and interact with their molecular target (Minchinton and Tannock, 2006) . However, up until now there has been no simple way to visualize directly the extent to which target engagement has been achieved in vivo.
One approach to monitor ligand binding to GPCRs in living cells is through the use of fluorescent ligands (Baker et al., 2011; Vernall et al., 2014; Stoddart et al., 2016) . However, uptake into cells can often lead to high levels of non-specific binding. We have recently dramatically improved the study of fluorescent ligand binding by developing a bioluminescence resonance energy transfer (BRET) assay that requires close proximity (circa 10 nm) between the fluorescent ligand and the target receptor to generate a measurable signal (Stoddart et al., , 2018 . This has been achieved using GPCRs tagged with a very bright luciferase (NanoLuc; Stoddart et al., , 2018 . This technological advance allowed us to monitor binding to the human b 2 -adrenoceptor in real time using a red fluorescent analog of the antagonist propranolol, propranolol-(b-Ala-b-Ala)-X-BODIPY 630/650 (Prop-BY630;  Figure S1 ). Here we have used this fluorescent ligand in conjunction with a triple-negative human breast cell line HM ) expressing an N-terminal NanoLuc-tagged human b 2 -adrenoceptor to quantify ligand binding (using NanoBRET) to a GPCR in vivo using a mouse model of breast cancer.
RESULTS AND DISCUSSION
We began by generating an MDA-MB-231 HM cell line stably expressing the human b 2 -adrenoceptor with an N-terminal NanoLuc tag. Standard fluorescence confocal microscopy revealed some of the limitations of using a fluorescent probe without BRET ( Figure 1A ). Thus, following incubation with a fluorescent analog of the b-blocker propranolol (50 nM; Prop-BY630; Figure S1 ), fluorescence was detected by confocal imaging at both the cell membrane and in a discrete perinuclear region ( Figure 1A ; lower left panel). Cell membrane fluorescence was completely prevented by co-incubation with 10 mM unlabelled propranolol ( Figure 1A ; lower right panel), demonstrating specific binding of the ligand to the b 2 -adrenoceptors on the cell surface. Perinuclear labeling, however, was not displaced by co-incubation with 10 mM unlabelled propranolol indicating non-specific binding. Furthermore, only non-specific binding was detected in nontransfected MDA-MB-231 HM cells ( Figure 1A ; upper left panel). This demonstrates that although confocal microscopy can detect cell surface receptors using fluorescent ligands, interpretation of the fluorescence readout may be confounded in an in vivo setting by the extent of non-specific binding to non-receptor sites.
To determine if BRET with NanoLuc-tagged receptors in combination with fluorescent ligands had the specificity required to detect ligand-binding to GPCRs on the surface of cancer cells, we first used widefield bioluminescence imaging to demonstrate the cell membrane location of the NanoLuc-tagged b 2 -adrenoceptor in MDA-MB-231 HM cells ( Figure 1B ; left panels). Addition of 50 nM Prop-BY630 allowed us to visualize the energy transfer from the N-terminal NanoLuc of the b 2 -adrenoceptor to the fluorescent ligand bound to the receptor via NanoBRET (detected in the Cy5 channel). This clearly revealed specific binding to cell surface b 2 -adrenoceptors that could be inhibited by a selective b 2 -antagonist ICI 118551 (10 mM; p < 0.001; Figures 1B and 1C) . The BRET signal from this ligand-receptor interaction was also measured in a 96-well plate format using a CLARIOstar plate reader, and demonstrated that the specific binding detected by BRET increased with the concentration of the probe until all of the receptors on the cell surface had been occupied. This specific binding (the difference between total binding and non-specific binding) was clearly saturable (pK D = 7.28 G 0.07; n = 5; Figure 2A ) and equally important for the future in vivo experiments; non-specific binding to non-receptor sites (obtained in the presence of 10 mM ICI 118551) was very low (Figure 2A ; closed circles).
To determine the compatibility for in vivo studies, we also imaged the BRET signal using a whole-animal bioluminescence and fluorescence imaging system, IVIS Lumina II ( Figure S2A ), and obtained a comparable pK D for fluorescent propranolol (7.26 G 0.06, n = 5). This was consistent with the value obtained previously for this ligand in HEK293 cells . The BRET methodology also allowed us to determine the binding kinetics of fluorescent propranolol (k on 5.4 G 2.2 3 10 5 M À1 min À1 ; k off 0.025 G 0.004 min À1 ; n = 5; Figure 2B ). This confirmed that Prop-BY630 could bind rapidly to the b 2 -adrenoceptor, but once bound dissociated slowly (the reciprocal of k off gives a residence time of 40 min), making it an ideal probe for in vivo use. Similar data for ligand binding kinetics/residence time were obtained in separate experiments using the IVIS system ( Figure S2B ).
To ensure that the BRET signal detected was confined to the b 2 -adrenoceptor, competition-binding experiments were undertaken with the b 2 -adrenoceptor-selective antagonist ICI 118 551, the b 1 -selective antagonist CGP 20712A (Gherbi et al., 2015) , and the non-selective b-blocker propranolol ( Figure 2C ). These experiments yielded pK i values that were consistent with literature values obtained previously for binding to b 2 -adrenoceptors Figures 2C, S2C , and S2D; Table S1 ). Thus, the b 1 -selective antagonist CGP 20712A produced very little inhibition of fluorescent ligand binding at concentrations up to 10 mM ( Figure 2C ). These data confirm that this BRET proximity assay is exquisitely selective and only detects binding to NanoLuc-tagged b 2 -adrenoceptors expressed on the tumor cells. Furthermore, our data also confirmed that the optical properties of the IVIS system had the sensitivity to detect ligand binding to b 2 -adrenoceptors on cancer cells by BRET ( Figure S2 ).
Previous work from our laboratory has shown that b 2 -adrenoceptors on MDA-MB-231 HM cells may play a significant role in the effect of stress on metastasis (Le et al., 2016; Sloan et al., 2010; Chang et al., 2016) . Those studies used tumor cells that had been transfected with a cytosolic firefly luciferase marker to monitor primary tumor growth and metastasis in a mouse model of breast cancer (Le et al., 2016; Sloan et al., 2010; Chang et al., 2016) . Cytosolic NanoLuc luciferase has also been used to monitor cancer progression in living animals (Stacer et al., 2013) . In contrast, here we used receptor-specific NanoLuc bioluminescence to localize in vivo tumor cells that specifically express b 2 -adrenoceptors. In mice injected with tumor cells into the mammary fat pad, luminescence intensity from NanoLuc-b 2 -adrenoceptors (photons/sec) increased from 8 days after tumor cell injection (Figures 3A and 3B) and correlated with primary tumor size determined by caliper (mm 3 ; Pearson correlation: p < 0.0001, R 2 = 0.560; Figure 3A ). Metastatic tumors containing cells expressing b 2 -adrenoceptors appeared in the lung and axillary lymph nodes later in tumor development ( Figure 3C ).
To detect ligand binding in vivo by BRET we injected Prop-BY630 (0.1 mg/kg) directly into the tumor (intratumoral [IT] ) and used the IVIS Lumina II imaging system to monitor the red fluorescence emission from the fluorescent ligand relative to the blue luminescence donor emission from the NanoLuc-labeled b2-adrenoceptors. This ratiometric approach determines the level of specific ligand binding independently of the number of cells expressing NanoLuc-b 2 -adrenoceptors present in the tumor. Thus, regardless of the slight variation in tumor burden between mice, we were able to compare how well Prop-BY630 interacted with the target b 2 -adrenoceptor on tumor cells. Preliminary experiments established that addition of 0.1 mg/kg Prop-BY630 delivered directly into the tumor reached a steady plateau BRET ratio, significantly above baseline values (n = 7; p < 0.001; two-way ANOVA), within circa 15 min of administration of the fluorescent ligand ( Figure S3 ). Figure 4B ). These data demonstrate the ability of this assay to accurately report target engagement in vivo. The data obtained with ICI 188551 indicate that 1 mg/kg (IV) is a dose that achieves roughly 50% target engagement of tumor cell b 2 -adrenoceptors within this solid breast cancer tumor model ( Figure 5 ).
Finally, to establish the sensitivity of the assay to different doses of the fluorescent ligand, we monitored in vivo ligand-binding BRET responses following addition of 0.01, 0.03, or 0.1 mg/kg of Prop-BY630 and quantified the in vivo receptor residence times over 72 hr ( Figure 6 ). These experiments demonstrated significant ligand binding that could be detected by BRET with all 3 doses of the fluorescent ligand in a dose-dependent manner ( Figure 6 ). Furthermore, binding of each of the 3 doses of Prop-BY630 to tumor b 2 -adrenoceptors was maintained for at least 48 hr after initial drug application ( Figure 6 ). These data are consistent with the slow off-rate kinetics of Prop-BY630 from the b2-adrenoceptor observed in vitro (Figure 2) and also suggest that the drug is not rapidly cleared from the tumor environment.
The close proximity requirements (10 nm) for BRET to occur between the donor NanoLuc on the N-terminus of human b 2 -adrenoceptors on tumor cells and the receptor-bound Prop-BY630 therefore provides a very sensitive and selective ligand binding assay to monitor receptor target engagement in tumors in vivo. As a consequence, the BRET readout should not be influenced by fluorescent ligand binding to neighboring endogenous receptors on other cell types (e.g., vascular and immune cells) within the tumor microenvironment. We therefore believe that this approach has significant advantages in specificity over other in vivo imaging modalities such as positron emission tomography (Hazan et al., 2017) for the study of specific receptor target engagement in tumors. In summary, the present study has shown that ligand binding to a GPCR can be monitored in vivo using BRET. Here we have used triple-negative human breast cancer cells expressing human b 2 -adrenoceptors tagged with the bioluminescence protein NanoLuc to demonstrate that parenterally applied drugs can access receptors on tumor cells in a mouse model of breast cancer. This in vivo NanoBRET method will be widely applicable to monitor target engagement in animal models for other cell surface receptors such as receptor tyrosine kinases (Kilpatrick et al., 2017) and for intracellular kinases .
Limitations of Study
The resolution of in vivo nanoBRET was limited in the present study to the detection of established tumors including macro-metastases. Future development of fluorescent ligands with increased water solubility should increase the stability in plasma and improve the detection of IV-administered probes. The development of new nanoluciferase substrates should also improve the in vivo detection of resonance energy transfer.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file. De Giorgi, V., Grazzini, M., Benemei, S., Marchionni, N., Botteri, E., Pennacchioli, E., Geppetti, P., and Gandini, S. 
SUPPLEMENTAL INFORMATION

Supplemental Information
Visualising ligand-binding to a GPCR in vivo using nanoBRET. (in 50µl of PBS) directly into the primary tumour (intratumoral; i.t). Immediately following this, mice were injected with 100µL 1:20 dilution furimazine substrate via the tail vein (i.v., 100µL diluted in PBS; circa 0.37 mg/kg) and imaged using the IVIS lumina II camera system. Mice were kept under 2-3% isoflurane anaesthesia during injections and imaging. Sequential luminescence (open channel, 30 sec exposure time) and fluorescence (Cy5.5. channel using 660/20nm bandpass filter; 5 min exposure time) images were taken every 6 min for a total time of 49 min. Images were acquired from 1 min after fluorescent ligand injection. Values show mean + S.E from seven mice. 2-Way ANOVA confirmed that there was a significant time-dependent effect (p<0.001). Table S1 . Table of following abbreviations are used to described signal shapes and multiplicities; singlet (s), doublet (d), triplet (t), quadruplet (q), broad (br), dd (doublet of doublets), ddd (double doublet of doublets), dtd (double triplet of doublets) and multiplet (m). Spectra were assigned using appropriate COSY and HSQC experiments. Processing of the NMR data was carried out using the NMR software Topspin 3.0. LC-MS spectra were recorded on a Shimadzu UFLCXR system coupled to an Applied Biosystems API2000 and visualised at 254 nm (channel 1) and 220 nm (channel 2). LC-MS was carried out using a Phenomenex Gemini-NX C18 110A, column (50 mm × 2 mm x 3 μm) at a flow rate 0.5 mL/min over a 5 min period (Method A). All high resolution mass spectra (HRMS) were recorded on a Bruker microTOF mass spectrometer using MS electrospray ionization operating in positive ion mode. RP-HPLC was performed on a Waters 515 LC system and monitored using a Waters 996 photodiode array detector at wavelengths between 190 and 800 nm. Spectra were analysed using Millenium 32 software. Semi-preparative HPLC was performed using YMC- The title compound was synthesised as previously described in the literature (Baker et al., 2011 ).
(±)-tert-Butyl 2-(2-hydroxy-3-(naphthalen-1-yloxy)propylamino)ethylcarbamate (2)
A solution of (±)-2-((naphthalen-1-yloxy)methyl)oxirane (1) (0.241 g, 1.20 mmol) and tertbutyl-2-aminoethylcarbamate (0.482 g, 3.01 mmol) in a mixture of DMF/water 9:1 (6 mL), was heated at 85°C for 16 hours. The solvent was removed under reduced pressure and the crude product was purified by column chromatography on silica (3% 1M NH3 in MeOH/DCM). The title compound was afforded as an off-white solid (0.168g, 39%). 41, 154.36, 134.63, 127.68, 126.60, 125.94, 125.65, 125.45, 121.91, 120.85, 105.08, 70.62, 68.59, 53.57, 51.90, 49.52, 28.55 
(±)-2-(2-Hydroxy-3-(naphthalen-1-yloxy)propyl-amino)ethylamine dihydrochloride (3)
To a solution of (±)-tert-butyl 2-(2-hydroxy-3-(naphthalen-1-yloxy)propylamino)ethylcarbamate (2) (0.063 g, 0.18 mmol) in Et2O (0.5 mL) 4M HCl in dioxane (0.5 mL) was added and the mixture was stirred for 5 hours. The solvent was removed under reduced pressure to afford the title compound as a pale pink solid (0.060 g, 100%). 35, 136.08, 128.59, 127.51, 126.92, 126.79, 126.28, 122.80, 121.98, 106.16, 71.05, 66.84, 51.97, 45.82, 36.69 
(±)-tert-Butyl(3-((2-((2-hydroxy-3-(naphthalen-1-yloxy)propyl)amino)ethyl)amino)-3-oxopropyl)carbamate (4)
To Boc-β-Ala-OH (0.090 g, 0.47 mmol) in DMF (2 mL) HBTU (0.213 g, 0.56 mmol) and DIPEA (0.302 g, 2.34 mmol) were added. The mixture was stirred for 10 minutes and (±)-2-(2-Hydroxy-3-(naphthalen-1-yloxy)propyl-amino)ethylamine dihydrochloride (3) 
(±)-3-((2-((2-Hydroxy-3-(naphthalen-1-yloxy)propyl)amino)ethyl)amino)-3-oxopropylamine ditrifluoroacetate (5)
To a solution of (±)-tert-butyl(3-((2-((2-hydroxy-3-(naphthalen-1-yloxy)propyl)amino)ethyl)amino)-3-oxopropyl)carbamate (4) (0.072 g, 0.17 mmol) in DCM (0.5 mL), TFA (0.5 mL) was added. The mixture was stirred at room temperature for 2 hours and the solvent was then removed under reduced pressure to afford the title compound as an off-white viscous solid which was used directly in the next step (0.054 g, 100% 
(±)-tert-Butyl-(3-((3-((2-((2-hydroxy-3-(naphthalen-1-yloxy)propyl)amino)ethyl)amino)-3-oxopropyl)amino)-3-oxopropyl)carbamate (6)
The synthesis of the title compound 6 was carried out as described for (±)-tert-butyl(3-((2-((2-hydroxy-3-(naphthalen-1-yloxy)propyl)amino)ethyl)amino)-3-oxopropyl)carbamate (4), using (±)-3-((2-((2-hydroxy-3-(naphthalen-1-yloxy)propyl)amino)ethyl)amino)-3-oxopropylamine ditrifluoroacetate (5). The title compound was afforded as an off-white viscous solid (0.034 g, 41%). 17, 155.35, 155.01, 136.08, 135.11, 130.26, 128.58, 127.51, 127.51, 126.92, 126.79, 126.28, 125.33, 122.79, 121.98, 118.74, 118.31, 106.16, 71.05, 66.84, 51.97, 45.82, 36.69 .
LC-MS m/z calc. for C26H39N4O6 [MH]
+ ; 503.3, found; 503.3, tR = 2.25 min. 3-((3-((2-((2-Hydroxy-3-(naphthalen-1-yloxy) propyl)amino)ethyl)amino)-3-oxopropyl)amino)-3-oxopropylamine dihydrochloride (7)
(±)-
Deprotection of (±)-tert-butyl-(3-((3-((2-((2-hydroxy-3-(naphthalen-1-yloxy)propyl)amino)ethyl)amino)-3-oxopropyl)amino)-3-oxopropyl)carbamate (6) (0.082 g, 0.16 mmol) was carried out as described for the synthesis of (±)-2-(2-Hydroxy-3-(naphthalen-1-yloxy)propyl-amino)ethylamine dihydrochloride (3). The title compound was afforded as a white solid (0.019 g, 29%). Hz, 2H), 2.60 (t, J = 6.5 Hz, 2H), 2.45 (t, J = 6.5 Hz, 2H), 1.41 -1.35 (m, 1H).
C NMR (101
MHz, CD3OD) δ 175. 66, 172.33, 155.40, 136.05, 128.54, 127.49, 126.93, 126.81, 126.28, 122.88, 121.90, 106.16, 71.15, 68.13, 66.86, 51.53, 37.16, 37.11, 37.06, 36.76, 33 .00, cDNA Construct.
LC-MS
The b2-adrenoceptor cDNA sequence (obtained from Missouri S&T cDNA Resource Centre;
www.cdna.org) was PCR amplified to generate a b2-adrenoceptor sequence that was in frame with the BamH1 restriction site of sig-NLuc and sig-SNAP (Gherbi et al., 2015) and changed the start codon (Met) of the b2-adrenoceptor sequence to
Leu. The primers used were: forward 5'-CCGCCGGATCCCTGGGGCAACCCGGGAACG-3'
and reverse 5'-GGCGGGAATTCTTACAGCAGTGAGTCATTTG-3'. The PCR product was then ligated in frame into pcDNA3.1(+) containing sig.SNAP 3 or sig-NLuc 1 using BamHI and EcoRI restriction enzymes. This created the plasmids sig-SNAP-ADRB2-pcDNA3.1(+) and sig-NLuc-ADRB2-pcDNA3.1(+).
The pSIN-SNAP-ADRB2 construct was generated on the basis of pSIN-eGFP-BSD lentiviral vector (Dixon et al., 2011) as following: first, the pSIN-eGFP-BSD plasmid was digested with SpeI and EcoRI restriction enzymes in order to remove eGFP sequence and to produce the pSIN/BSD backbone; second, SNAP-ADRB2 fragment was PCR amplified with 5'-CTTAAACTAGTTACCGCCACCATGCGGCTCTGC-3' (forward) and 5'-TCTGCAGAATTCttacagcagtgagtcatttg-3' (reverse) primers using sig-SNAP-ADRB2-pcDNA3.1(+) as a template. The resulting PCR product was digested with SpeI and EcoRI restriction endonucleases and ligated into eGFP-free pSIN/BSD backbone. To make the pSIN-NLuc-ADRB2 construct, a NheI-EcoRI fragment containing the NanoLuc-ADRB2 fusion sequence was isolated from sig-NLuc-ADRB2-pcDNA3.1(+) and used to replace SpeI-EcoRI SNAP-ADRB2 sequence in pSIN-SNAP-ADRB2.
Cancer cell model.
This study used a highly metastatic variant of the female MDA-MB-231 triple-negative human breast cell line (MDA-MB-231 HM ; a kind gift from Dr. Zhou Ou, Fudan University Shanghai Cancer Center, China) (Chang et al., 2008) . Cell line identity was confirmed by short tandem repeat analysis. The cell line was stably transfected with the lentiviral vector pSIN-NLuc-ADRB2 encoding Nanoluc-β2-adrenoreceptor (Nluc-β2AR), using Fugene HD reagent, following the manufacturer's protocol, using a 3:1 reagent:DNA ratio. Transfected cells were selected using 20 µg/mL blastocidin (Sigma). 10 µg/mL blastocidin was used for cell maintenance. Cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) containing 2mM Glutamax (Gilbco) supplemented with 10% foetal bovine serum. For in vivo use, blastocidin was removed from the growth medium for several passages.
Confocal microscopy.
Confocal microscopy was performed using a Leica TCS SP8 inverted scanning microscope Images were analysed using ImageJ 1.51 (Fiji, USA) software.
Widefield bioluminescence microscopy.
Bioluminescence imaging was performed using an Olympus LV200 Wide field inverted microscope, equipped with a 60x/1.42NA oil immersion objective lens. MDA-MB-231 HM cells transfected with NanoLuc-tagged human β2-adrenoceptors were seeded into a 35mm
MatTek dish containing a high tolerance 1.5μm coverslip. Before imaging, media was removed and cells were incubated with 2mL HBSS containing 400nM furimazine substrate In vitro NanoBRET assays.
Saturation, competition and kinetics NanoBRET binding assays were performed on MDA-MB-231 HM cells stably expressing NanoLuc-tagged b2-adrenoceptors as described previously . Briefly, cells were seeded 24h before assay in white Perkin Elmer 96-well Isoplates. For experiments performed under equilibrium conditions, growth media was replaced with 100μL HBSS. Fluorescent and non-fluorescent ligands were added simultaneously and the 96-well plate was incubated for 1h at 37 °C (no CO2).
10μL NanoLuc substrate furimazine (Promega) was then added to give a final concentration of 10µM and the plate was incubated for a further 5 minutes at 37 °C. For all experiments, the luminescence was measured using a CLARIOstar plate reader (BMG Labtech) with filtered light emission collected at 685nm/100nm bandpass (acceptor) and 460nm/80nm bandpass (donor) at room temperature. The raw BRET ratio was calculated by dividing the 685nm emission by the 460nm emission. The same experiments were also performed using the IVIS Lumina II whole-animal imaging system (Caliper Life Sciences, Perkin Elmer) using both an open channel (donor; 1 sec exposure time) and the CY5.5 channel (acceptor; 660/20nm bandpass; 30 sec exposure time).
For kinetics binding assays, growth media from cells was replaced with 50μL HBSS containing 10μM furimazine substrate, and incubated for 15 min, at 37 o C (without CO2).
50μL ligands, previously prepared in HBSS, were then added to wells and luminescence measurements were made every minute (for 60 min) with the above emission settings on both the CLARIOstar plate reader and the IVIS Lumina II system as described above.
Breast cancer in vivo model. injection of furimazine to determine luminescence (and BRET) baseline. Images were acquired as described above using the IVIS system, 5 min after furimazine substrate (100µL in PBS; 0.37 mg/kg) injection, using the same filter settings and exposure times as described above for the donor and acceptor readings. 
Data analysis.
In vitro pharmacological characterisation.
For analysis of saturation binding data, raw BRET ratios obtained from each individual experiment were fitted using a non-linear regression equation shown below, using GraphPad where Y is the specific binding at time t, corresponds to the level of specific binding at infinite time and UWX is the rate constant for the observed rate of association.
In vivo data analysis.
In vivo luminescence or fluorescence total flux (photons/sec) measurements were obtained using ROIs positioned on the primary tumour or thorax region, for primary tumour or metastasis measurements, respectively. Raw BRET ratios were calculated as: where acceptor luminescence (Cy5.5 channel) is measured as total flux (photons/sec) acquired using the Cy5.5 emission channel (660nm/20nm bandpass), and luminescence (open channel) is measured as total flux (photons/sec) acquired without using emission filters.
Statistical analysis.
For in vitro and in vivo studies, one-way or two-way ANOVA analysis with Tukey's or Dunnett's multiple comparison tests were used.
